Cambridge Network is delighted to be able to invite you to join us, and our headline sponsor TTP, for an evening of panel discussions, company exhibitions and workshops. Taking place on the 3rd December from 6pm – 9pm, at the Post Doc Centre in Eddington, Cambridge.
The FREE event will offer practical advice and inspiration through a variety of activities, including:
ABOUT RXCELERATE
The RxCelerate Group is a drug discovery and development service provider with clients ranging from virtual biotech companies to global pharmaceutical organisations in Europe and the USA. We design and deliver a range of drug discovery projects from concept through to early clinical development and provide Project Management resources to our clients.
· EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies
· Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection
· Data presented at AASLD Liver Meeting, held 15-19 November 2024, San Diego, CA
Virtual business development & licensing event
We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst. As part of our series of diversity and inclusion events this year, which have included International Women’s Day and PRIDE, we hosted talks, a Q&A and a wellbeing workshop to promote gender inclusivity, equality and allyship at SBC.
CancerSeq™ FFPE tissues from AMSBIO are pre-screened tumor tissue samples for single nucleotide polymorphisms (SNP’s), insertions and deletions plus copy number variations (CNVs) using targeted Next Generation Sequencing to identify key mutations and mutational hotspots.
Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.